BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 15735124)

  • 21. Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI.
    Cheon GJ; Kim MS; Lee JA; Lee SY; Cho WH; Song WS; Koh JS; Yoo JY; Oh DH; Shin DS; Jeon DG
    J Nucl Med; 2009 Sep; 50(9):1435-40. PubMed ID: 19690035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
    Ferrari S; Smeland S; Mercuri M; Bertoni F; Longhi A; Ruggieri P; Alvegard TA; Picci P; Capanna R; Bernini G; Müller C; Tienghi A; Wiebe T; Comandone A; Böhling T; Del Prever AB; Brosjö O; Bacci G; Saeter G;
    J Clin Oncol; 2005 Dec; 23(34):8845-52. PubMed ID: 16246977
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical value of mitochondrial mutations in colorectal cancer.
    Lièvre A; Chapusot C; Bouvier AM; Zinzindohoué F; Piard F; Roignot P; Arnould L; Beaune P; Faivre J; Laurent-Puig P
    J Clin Oncol; 2005 May; 23(15):3517-25. PubMed ID: 15908662
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of serum alkaline phosphatase in osteosarcoma of the extremity treated with neoadjuvant chemotherapy: recent experience at Rizzoli Institute.
    Bacci G; Longhi A; Ferrari S; Lari S; Manfrini M; Donati D; Forni C; Versari M
    Oncol Rep; 2002; 9(1):171-5. PubMed ID: 11748477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRCA1 and TP53 mutation spectrum of breast carcinoma in an ethnic population of Kashmir, an emerging high-risk area.
    Eachkoti R; Hussain I; Afroze D; Aejazaziz S; Jan M; Shah ZA; Das BC; Siddiqi MA
    Cancer Lett; 2007 Apr; 248(2):308-20. PubMed ID: 16996204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma.
    Onda M; Matsuda S; Higaki S; Iijima T; Fukushima J; Yokokura A; Kojima T; Horiuchi H; Kurokawa T; Yamamoto T
    Cancer; 1996 Jan; 77(1):71-8. PubMed ID: 8630943
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intraarterial Cisplatin and intravenous adriamycin in nonmetastatic osteosarcoma of the extremities: a single institution experience in Taiwan.
    Chiu TJ; Wang JW; Chen YJ; Tang Y; Huang CH
    Chang Gung Med J; 2009; 32(1):72-80. PubMed ID: 19292942
    [TBL] [Abstract][Full Text] [Related]  

  • 28. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
    Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
    Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of immunohistochemical expression of ezrin in non-metastatic high-grade osteosarcoma.
    Ferrari S; Zanella L; Alberghini M; Palmerini E; Staals E; Bacchini P
    Pediatr Blood Cancer; 2008 Apr; 50(4):752-6. PubMed ID: 17886294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution.
    Bacci G; Mercuri M; Longhi A; Ferrari S; Bertoni F; Versari M; Picci P
    Eur J Cancer; 2005 Sep; 41(14):2079-85. PubMed ID: 16115755
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma.
    Mintz MB; Sowers R; Brown KM; Hilmer SC; Mazza B; Huvos AG; Meyers PA; Lafleur B; McDonough WS; Henry MM; Ramsey KE; Antonescu CR; Chen W; Healey JH; Daluski A; Berens ME; Macdonald TJ; Gorlick R; Stephan DA
    Cancer Res; 2005 Mar; 65(5):1748-54. PubMed ID: 15753370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TP53 in gastric cancer: mutations in the l3 loop and LSH motif DNA-binding domains of TP53 predict poor outcome.
    Migliavacca M; Ottini L; Bazan V; Agnese V; Corsale S; Macaluso M; Lupi R; Dardanoni G; Valerio MR; Pantuso G; Di Fede G; Tomasino RM; Gebbia N; Mariani-Costantini R; Russo A
    J Cell Physiol; 2004 Sep; 200(3):476-85. PubMed ID: 15254976
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer.
    Geisler S; Børresen-Dale AL; Johnsen H; Aas T; Geisler J; Akslen LA; Anker G; Lønning PE
    Clin Cancer Res; 2003 Nov; 9(15):5582-8. PubMed ID: 14654539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TP53 gene mutations in canine osteosarcoma.
    Kirpensteijn J; Kik M; Teske E; Rutteman GR
    Vet Surg; 2008 Jul; 37(5):454-60. PubMed ID: 18986312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. P53 mutation does not affect prognosis in ovarian epithelial malignancies.
    Fallows S; Price J; Atkinson RJ; Johnston PG; Hickey I; Russell SE
    J Pathol; 2001 May; 194(1):68-75. PubMed ID: 11329143
    [TBL] [Abstract][Full Text] [Related]  

  • 36. P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy.
    Baldini N; Scotlandi K; Serra M; Picci P; Bacci G; Sottili S; Campanacci M
    J Orthop Res; 1999 Sep; 17(5):629-32. PubMed ID: 10569469
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical importance of near-diploid tumor stem lines in patients with osteosarcoma of an extremity.
    Look AT; Douglass EC; Meyer WH
    N Engl J Med; 1988 Jun; 318(24):1567-72. PubMed ID: 3163773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma.
    Foster JM; Gatalica Z; Lilleberg S; Haynatzki G; Loggie BW
    Ann Surg Oncol; 2009 Jan; 16(1):152-8. PubMed ID: 18998063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Germ-line genetic variation of TP53 in osteosarcoma.
    Savage SA; Burdett L; Troisi R; Douglass C; Hoover RN; Chanock SJ;
    Pediatr Blood Cancer; 2007 Jul; 49(1):28-33. PubMed ID: 17096406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Primary versus radiation-associated craniofacial osteosarcoma: Biologic and clinicopathologic comparisons.
    McHugh JB; Thomas DG; Herman JM; Ray ME; Baker LH; Adsay NV; Rabah R; Lucas DR
    Cancer; 2006 Aug; 107(3):554-62. PubMed ID: 16795069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.